Confusion persists about the best choice of frontline therapy for patients with metastatic colorectal cancer (mCRC) after a landmark clinical trial that was conceived a decade ago to answer that question concluded without a superiority finding
Lauren Zoeller
Advertisement
Articles by Lauren Zoeller
Advertisement
Latest Updated Articles
Experts Emphasize Therapy Options, Expanded Mutation Testing in mCRCNovember 18th 2014
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL
5